A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Bayer
Seagen Inc.
Seagen Inc.
Pliant Therapeutics, Inc.
Pfizer
Eli Lilly and Company
Compass Therapeutics
Merck Sharp & Dohme LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Exelixis
Amgen
EMD Serono
The Methodist Hospital Research Institute
Bayer
Sotio Biotech Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Rondo Therapeutics
Mayo Clinic
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
Pfizer
Emory University
Incendia Therapeutics
Shanghai Henlius Biotech
Amgen
University of Rochester
Werewolf Therapeutics, Inc.
Royal Marsden NHS Foundation Trust
City of Hope Medical Center
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Novartis
Bio-Thera Solutions
AbelZeta Inc.
Amgen
Sairopa B.V.
Rutgers, The State University of New Jersey
Daiichi Sankyo
Coherus Oncology, Inc.
Merck Sharp & Dohme LLC
Nanobiotix
Hummingbird Bioscience
Peter MacCallum Cancer Centre, Australia
Tempest Therapeutics
Asher Biotherapeutics, Inc.
Valo Therapeutics Oy
Epkin
Takeda